환각제 시장 규모, 점유율, 성장 분석 : 원료별, 종류별, 약물별, 용도별, 투여 경로별, 최종사용자별, 유통 경로별, 지역별 - 업계 예측(2026-2033년)

Psychedelic Drugs Market size was valued at USD 3066.7 Million in 2024 and is poised to grow from USD 3474.57 Million in 2025 to USD 9434.98 Million by 2033, growing at a CAGR of 13.3% during the forecast period (2026-2033).

The market for psychedelic drugs is experiencing significant growth driven by heightened awareness of mental health treatment and the urgent need to address issues like stress, anxiety, and depression. These substances offer alternative mechanisms for managing mental conditions, with varying degrees of effectiveness. Initiatives from governments and mental health organizations are fostering this growth, as increased prevalence of mood disorders, notably among youth, creates a greater demand for innovative treatments. Although challenges remain, such as side effects and regulatory hurdles, the expanding acceptance of psychedelics in therapeutic settings bodes well for the industry. Continued investment and research into these drugs suggest a promising future, making the psychedelic drug market a key area for stakeholders to monitor amid ongoing developments in mental health care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Psychedelic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Psychedelic Drugs Market Segments Analysis

Global Psychedelic Drugs Market is segmented by source, type, drug, application, route of administration, end-user, distribution channel and region. Based on source, the market is segmented into synthetic and natural. Based on type, the market is segmented into empathogens, dissociatives and others. Based on drug, the market is segmented into gamma-hydroxybutyric acid (GHB), ketamine, psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA) and others. Based on application, the market is segmented into narcolepsy, treatment-resistant depression, major depressive disorder, opiate addiction, post-traumatic stress disorder (PTSD) and others. Based on route of administration, the market is segmented into oral, inhalation and injectable. Based on end-user, the market is segmented into hospitals, specialty clinics, homecare and others. Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Psychedelic Drugs Market

The popularity of psychedelic drugs has surged as they emerge as potential solutions for mental health treatment and healing. Their ability to alleviate conditions like depression has captured the interest of researchers and scientists who are exploring their therapeutic value. With ongoing innovation and research in this field, there is a growing acceptance and recognition of psychedelic medications, driving their use and adoption. This escalating interest and success observed in various applications have significantly contributed to the increasing demand for psychedelic substances across various regions, highlighting the potential of these drugs as major drivers in the market.

Restraints in the Psychedelic Drugs Market

The growth of the psychedelic drugs market is likely to be hindered by the substantial expenses associated with these substances. Additionally, the presence of rigid regulations and compliance requirements presents further obstacles that may affect market expansion. These financial and regulatory challenges create an environment that could slow the adoption and accessibility of psychedelic drugs, ultimately restraining overall market growth. As the industry navigates these complexities, the combination of high costs and stringent legislative frameworks could limit the potential for wider acceptance and integration of these products in healthcare and therapeutic settings.

Market Trends of the Psychedelic Drugs Market

The psychedelic drugs market is witnessing a notable trend towards the growth of the hospital pharmacy segment, fueled by heightened public awareness surrounding mental health issues and the therapeutic potential of psychedelics. As more individuals seek professional help, the demand for these substances, which necessitate prescriptions from medical practitioners, is surging. This shift is not only enhancing the role of hospital pharmacies as distribution channels but also catalyzing their involvement in the management of specific medical conditions. Consequently, this increasing integration of psychedelics into healthcare frameworks underscores a significant transformation in treatment paradigms and pharmacy operations.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies
• Customer & Buying Criteria Analysis

Global Psychedelic Drugs Market Size by Source & CAGR (2026-2033)

• Market Overview
• Synthetic
• Natural

Global Psychedelic Drugs Market Size by Type & CAGR (2026-2033)

• Market Overview
• Empathogens
• Dissociatives
• Others

Global Psychedelic Drugs Market Size by Drug & CAGR (2026-2033)

• Market Overview
• Gamma-Hydroxybutyric Acid (GHB)
• Ketamine
• Psilocybin
• Lysergic Acid Diethylamide (LSD)
• 3,4-Methylenedioxymethamphetamine (MDMA)
• Others

Global Psychedelic Drugs Market Size by Application & CAGR (2026-2033)

• Market Overview
• Narcolepsy
• Treatment-Resistant Depression
• Major Depressive Disorder
• Opiate Addiction
• Post-Traumatic Stress Disorder (PTSD)
• Others

Global Psychedelic Drugs Market Size by Route Of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Inhalation
• Injectable

Global Psychedelic Drugs Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Psychedelic Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Psychedelic Drugs Market Size & CAGR (2026-2033)

• North America (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • USA
  • Canada
• Europe (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Compass Pathways (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MindMed (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atai Life Sciences (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cybin Corp. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Field Trip Health (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GH Research (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckley Psytech (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seelos Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Numinus Wellness Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Delix Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mydecine Innovations Group (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Revive Therapeutics Ltd. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Entheon Biomedical (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mind Cure Health Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PsyBio Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tryp Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations